🇺🇸 FDA
Patent

US 7867974

Induction of tolerance by oral administration of factor VIII and treatment of hemophilia

granted A61KA61K38/27A61K38/36

Quick answer

US patent 7867974 (Induction of tolerance by oral administration of factor VIII and treatment of hemophilia) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jan 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jan 11 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K38/27, A61K38/36, A61K38/4846, A61K48/00